Skip to main content

Table 2 Main clinical laboratory values of COVID-19 follow-up patients

From: Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients

Laboratory values Reference ranges COVID-19 follow-up patients
Mild (n = 59) Severe/Critical (n = 48)
Adm Flw p Adm Flw p
LDL-c *109 (29) mg/dL 100.5 (87.0, 113.3) 103.6 (90.5, 116.0) 0.048 96.1 (74.3, 107.2) 103.6 (76.2, 123.4) 0.003
HDL-c *52 (15) mg/dL 52.9 (46.0, 64.2) 54.5 (46.8, 63.4) 0.297 50.3 (43.7, 65.4) 55.3 (46.0, 65.7) 0.042
TC *182 (34) mg/dL 197.9 (170.5, 223.5) 203.4 (187.2, 220.8) 0.042 192.4 (151.3, 221.6) 203.2 (152.1, 246.6) 0.016
Non-HDL-c *130 (35) mg/dL 144.2 (118.3, 160.8) 147.0 (125.3, 165.9) 0.039 135.7 (102.8, 157.4) 151.8 (103.7, 182.4) 0.009
TG *133 (99) mg/dL 165.5 (131.1, 219.6) 140.8 (108.1, 177.1) 0.001 141.7 (107.6, 182.2) 143.9 (111.6, 200.6) 0.376
WBC 3.5–9.5 (×109/L) 5.8 (5.2, 6.8) 5.4 (4.7, 6.2) 0.002 6.3 (5.0, 8.1) 5.6 (5.0, 6.7) 0.046
LY *2.1 (0.5) (× 109/L) 1.5 (1.3, 1.8) 1.9 (1.5, 2.2) <  0.001 1.6 (1.1, 1.9) 2.0 (1.5, 2.3) <  0.001
MO 0.1–0.6 (×109/L) 0.5 (0.3, 0.6) 0.3 (0.2, 0.4) <  0.001 0.5 (0.3, 0.7) 0.3 (0.3, 0.4) <  0.001
D-dimer <  0.5 mg/ml 0.5 (0.2, 0.8) 0.3 (0.2, 0.4) <  0.001 0.7 (0.4, 1.1) 0.4 (0.3, 0.5) <  0.001
ATIII 80–120% 90 (81.5, 96.5) 97 (89, 102.5) <  0.001 88 (81.2, 93.8) 96 (87, 102.8) 0.001
FDP <  5 μg/L 1.7 (1.1, 2.5) 1.1 (1, 1.5) <  0.001 2.7 (1.6, 3.7) 1.3 (1.0, 2.0) <  0.001
FIB 2–4 g/L 4.0 (3.4, 5.2) 3.2 (2.7, 3.5) <  0.001 4.6 (3.7, 5.5) 3.3 (3.0, 3.7) <  0.001
CRP <  4 mg/L 1.7 (0.6, 4.8) 1.4 (0.6, 2.2) <  0.001 2.9 (1.2, 8.3) 1.6 (1.1, 2.6) 0.002
ALT 5–35 U/L 36 (22, 54) 25 (19, 32) <  0.001 33.5 (21.8, 62.2) 21 (15, 32.4) 0.013
ALP 40–150 U/L 89 (72, 104) 77 (64, 87) <  0.001 91 (71, 107) 73 (64, 85) <  0.001
GGT 7–32 U/L 32 (22, 51) 23 (17, 32) <  0.001 31.5 (18.7, 50.5) 23 (18, 31) <  0.001
TBIL 5.1–19 μmol/L 11.5 (9.8, 14.6) 16.7 (12.2, 20.8) <  0.001 11.1 (8.8, 14.3) 13.2 (10.8, 15.9) 0.002
DBIL 1.7–6.8 μmol/L 3.1 (2.5, 3.6) 3.7 (3, 4.5) <  0.001 3.2 (2.4, 4.0) 3.2 (3, 3.7) 0.215
TBA 0–10 μmol/L 4.3 (3.2, 6.9) 2.5 (1.5, 3.7) <  0.001 4.7 (3.3, 7.7) 2.6 (1.3, 4.6) <  0.001
TP 64–83 g/L 70.6 (67.6, 74.7) 73.8 (71.9, 77.2) <  0.001 68.9 (65.4, 72.3) 75.4 (72.8, 79.5) <  0.001
GLB 20–30 g/L 28.6 (26.4, 31.7) 27.4 (24.7, 29.7) 0.002 28.9 (26.4, 32.6) 29.0 (25.5, 31.8) 0.506
ALB 35–55 g/L 41.9 (39.4, 44) 46.8 (45.7, 49) <  0.001 37.4 (6.4) 46.5 (2.7) <  0.001
A/G ratio 1.5–2.5 1.5 (1.3, 1.6) 1. 7 (1.5, 1.9) <  0.001 1.3 (1.2, 1.5) 1.6 (1.5, 1.8) <  0.001
  1. *Data are adapted from age and gender-matched normal subjects from the city of Wuhan [11]. Data are presented as mean (SD) in reference ranges or median (IQR) unless stated otherwise. A Wilcoxon signed-rank test (two-sided) is used to compare variables at the times of admission with follow-up from the same subjects within groups (mild and severe/critical cases)
  2. Adm at time of admission, Flw follow-up, ATIII antithrombin III, FDP fibrin degradation product, FIB fibrinogen, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transferase, WBC white blood cell, LY lymphocyte, MO monocyte, TC total cholesterol, TG triglycerides, TP total protein, ALB albumin, GLB globulin, TBIL total bilirubin, DBIL direct bilirubin, CRP C-reactive protein, TBA total bile acid, A/G ALB/GLB ratio